Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lyra Therapeutics ( (LYRA) ) just unveiled an update.
Lyra Therapeutics announced changes to its Board of Directors with the resignations of Michael Altman and Konstantin Poukalov. To maintain an equal balance among board classes, Maria Palasis, Ph.D. shifted from Class III to Class I, resulting in her resignation and immediate re-election, ensuring her service remained uninterrupted.
More about Lyra Therapeutics
YTD Price Performance: -96.15%
Average Trading Volume: 1,583,200
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.22M
For an in-depth examination of LYRA stock, go to TipRanks’ Stock Analysis page.